GlassScriptPhysician profile
Cheryl A Sorn
NPI 1245610682
$6,163.29
in general payments reported to CMS, 2019-2025
39 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,172 · 2022: $1,046 · 2023: $1,187 · 2024: $963 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $852.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $839.89 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $573.38 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $455.12 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $451.61 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $340.35 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Orexo US, INC. | $251.20 | 2021-2025 | Zubsolv |
| Axsome Therapeutics, INC. | $228.48 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $204.81 | 2023-2025 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $156.20 | 2022 | |
| Amgen INC. | $145.29 | 2021-2023 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $135.00 | 2025 | Cobenfy |
| Exact Sciences Corporation | $131.64 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $131.41 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $126.43 | 2023-2025 | Rexulti |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Sorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.